Trial · NCT00723554
Outcomes44
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 44
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Reporting Treatment-emergent Adverse Events (AEs) | From the first dose to last dose of investigational product, an average of approximately 268 days, plus 48 hours | Safety population | participants | NUMBER |
| PRIMARY | Number of Patients Who Discontinued Iloprost PD-15 Treatment Due to an AE | From the first dose of investigational product to study discontinuation, an average of approximately 268 days | Safety population | participants | NUMBER |
| PRIMARY | Number of Patients Reporting Treatment-emergent Serious AEs | From the first to last dose of investigational product, an average of approximately 268 days, plus 48 hours | Safety population | participants | NUMBER |
| PRIMARY | Systolic Blood Pressure - Iloprost PD-6 (Period 1) | Day 1 | Safety population | mmHg | MEAN |
| PRIMARY | Systolic Blood Pressure - Iloprost PD-15 (Period 2) | Day 28 | Safety population - missing data were not imputed | mmHg | MEAN |
| PRIMARY | Systolic Blood Pressure - Iloprost PD-15 (Period 3) | an average of approximately 268 days | Safety population - missing data were not imputed | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure - (Period 1 to Period 2) | Day 1 and Day 28 | Safety population - missing data were not imputed | mmHg | MEAN |
| PRIMARY | Change in Systolic Blood Pressure - (Period 1 to Period 3) | Day 1 and End of study visit, an average of approximately 268 days | Safety population - missing data were not imputed | mmHg | MEAN |
| PRIMARY | Diastolic Blood Pressure - Iloprost PD-6 (Period 1) | Day 1 | mmHg | MEAN | |
| PRIMARY | Diastolic Blood Pressure - Iloprost PD-15 (Period 2) | Day 28 | Safety population - missing data were not imputed | mmHg | MEAN |
| PRIMARY | Diastolic Blood Pressure - Iloprost PD-15 (Period 3) | an average of approximately 268 days | Safety population - missing data were not imputed | mmHg | MEAN |
| PRIMARY | Change in Diastolic Blood Pressure - (Period 1 to Period 2) | Day 1 and Day 28 | Safety population - missing data were not imputed | mmHg | MEAN |
| PRIMARY | Change in Diastolic Blood Pressure - (Period 1 to Period 3) | Day 1 and End of study visit, an average of approximately 268 days | Safety population - missing data were not imputed | mmHg | MEAN |
| PRIMARY | Heart Rate - Iloprost PD-6 (Period 1) | Day 1 | Safety population | beats per minute | MEAN |
| PRIMARY | Heart Rate - Iloprost PD-15 (Period 2) | Day 28 | Safety population - missing data were not imputed | beats per minute | MEAN |
| PRIMARY | Heart Rate - Iloprost PD-15 (Period 3) | an average of approximately 268 days | Safety population - missing data were not imputed | beats per minute | MEAN |
| PRIMARY | Change in Heart Rate - (Period 1 to Period 2) | Day 1 and Day 28 | Safety population - missing data were not imputed | beats per minute | MEAN |
| PRIMARY | Change in Heart Rate - (Period 1 to Period 3) | Day 1 and End of study visit, an average of approximately 268 days | Safety population - missing data were not imputed | beats per minute | MEAN |
| SECONDARY | Average Inhalation Time - Iloprost PD-6 (Period 1) | average of approximately 28 days | Modified intent-to-treat (MITT) population - includes all enrolled patients without major protocol violations, who received at least one dose of iloprost with PD-15, and had one or more post-baseline evaluations for pharmacodynamic endpoints. | minutes | MEAN |
| SECONDARY | Average Inhalation Time - Iloprost PD-15 (Period 2) | average of approximately 28 days | Modified intent-to-treat (MITT) population - includes all enrolled patients without major protocol violations, who received at least one dose of iloprost with PD-15, and had one or more post-baseline evaluations for pharmacodynamic endpoints. | minutes | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00723554/outcomes